TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07265258: A Multicenter, Randomized, Open-Label, Active-Controlled Phase IV Clinical Study to Evaluate the Efficacy and Safety of Teprotumumab N01 in the Treatment of Active Thyroid Eye Disease

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 92 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT07265258 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07265258 Rescue Dossier →